Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-hydroxy‑1,2,5‑oxadiazole‑3‑carboxylic acid is a small molecule belonging to the class of furazans (also known as oxadiazoles), characterized by a five-membered heterocyclic ring containing nitrogen and oxygen atoms. It has the molecular formula C₃H₂N₂O₄ and is primarily used in research settings. The compound has been identified as an experimental drug with no approved medical indications or clinical trial activity beyond preclinical investigation. It is known to interact with L-lactate dehydrogenase and L-lactate dehydrogenase B chain in biochemical studies; however, its precise mechanism of action remains uncharacterized[1][2][4]. There are no reported therapeutic uses or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid.